Literature DB >> 24758314

Expression of Epstein-Barr virus in children with sacrococcygeal pilonidal sinus determined by immunohistochemical methods.

Esra Karakuş1, Ayper Kaçar2, Resul Karakuş3, Ervin Mambet4, Atilla Şenaylı4.   

Abstract

In this study, we probed whether chronic infections of skin such as pilonidal sinus could be a potential site of Epstein-Barr virus (EBV) replication. Pilonidal sinus is associated with a high recurrence rate. Therefore, we decided to determine the role of EBV's presence to explain whether it is correlated with the recurrence of pilonidal sinuses. This study was conducted on 36 patient samples with sacrococcygeal pilonidal sinus. Samples were immunohistochemically stained for EBV, CD3 and CD20 expression. Thirty-six adolescents with pilonidal disease were evaluated. EBV-positive cells were located in dermis with high inflammatory activity. EBV-positive cells stained positive for the B-cell antigen CD20 and were detected in 10 of 36 (27%) pilonidal sinus specimens. Among those who had experienced a relapse, three were positive for EBV expression. In addition, EBV expression was detected in eight cases with severe inflammation, and in two with minimal or moderate inflammation. Our study advances the field by demonstrating that similar to gastrointestinal mucosa, skin could be a reservoir for EBV. EBV was found to be restricted to B cells in skin lesions, and it was found that skin lesions with severe inflammation showed higher frequency of EBV expression in comparison to minimal or moderately inflammed skin lesions. Additionally, recurrence was more frequently observed among EBV-positive cases. These findings point out for a role of EBV infection in the recurrence of pilonidal sinuses.
© 2014 The Authors. International Wound Journal © 2014 Medicalhelplines.com Inc and John Wiley & Sons Ltd.

Entities:  

Keywords:  Epstein-Barr virus; Inflammation; Pilonidal sinus; Skin chronic inflammation

Mesh:

Substances:

Year:  2014        PMID: 24758314      PMCID: PMC7949730          DOI: 10.1111/iwj.12286

Source DB:  PubMed          Journal:  Int Wound J        ISSN: 1742-4801            Impact factor:   3.315


  8 in total

Review 1.  Overview and problematic standpoints of severe chronic active Epstein-Barr virus infection syndrome.

Authors:  Motohiko Okano
Journal:  Crit Rev Oncol Hematol       Date:  2002-12       Impact factor: 6.312

2.  High frequency of Epstein-Barr virus-infected lymphocytes in pilonidal cysts.

Authors:  Geisilene Russano de Paiva; Nivaldo Adolfo da Silva; Michel March; Pierre Brousset; Camille Laurent
Journal:  Hum Pathol       Date:  2012-06-28       Impact factor: 3.466

Review 3.  Epstein-Barr virus infection and its role in the expanding spectrum of human diseases.

Authors:  M Okano
Journal:  Acta Paediatr       Date:  1998-01       Impact factor: 2.299

4.  Azathioprine-induced EBV-positive mucocutaneous ulcer.

Authors:  Jamie L McGinness; Kerith E Spicknall; Diya F Mutasim
Journal:  J Cutan Pathol       Date:  2012-01-11       Impact factor: 1.587

5.  Epstein-Barr virus infection is common in inflamed gastrointestinal mucosa.

Authors:  Julie L Ryan; You-Jun Shen; Douglas R Morgan; Leigh B Thorne; Shannon C Kenney; Ricardo L Dominguez; Margaret L Gulley
Journal:  Dig Dis Sci       Date:  2012-03-13       Impact factor: 3.199

Review 6.  Sacrococcygeal pilonidal sinus: historical review, pathological insight and surgical options.

Authors:  S Chintapatla; N Safarani; S Kumar; N Haboubi
Journal:  Tech Coloproctol       Date:  2003-04       Impact factor: 3.781

7.  Surgery for asymptomatic pilonidal sinus disease.

Authors:  Dietrich Doll; Jan Friederichs; Anne-Laure Boulesteix; Wolfgang Düsel; Falko Fend; Sven Petersen
Journal:  Int J Colorectal Dis       Date:  2008-05-20       Impact factor: 2.571

Review 8.  Mucocutaneous manifestations of Epstein-Barr virus infection.

Authors:  Natalia Mendoza; Melissa Diamantis; Anita Arora; Brenda Bartlett; Aron Gewirtzman; Anne-Marie Tremaine; Stephen Tyring
Journal:  Am J Clin Dermatol       Date:  2008       Impact factor: 7.403

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.